Indrayani Biotech Limited has announced a board meeting on which it approved the audited financial results for the quarter and year ended March 31, 2025, with an unmodified auditor report.

The standalone revenue from operations for the year stood at Rs 37.77 Cr, with a net profit of Rs 1.45 Cr and earnings per share of Rs 0.32. The company reported stable cost control and increased borrowings, with total assets rising to Rs 130.68 Cr.

Additionally, the Company Secretary and Compliance Officer, Mr. V. Santhanakrishnan, resigned to pursue other opportunities, effective June 13, 2025. The meeting was adjourned to approve consolidated financials next.